A large retrospective study conducted by physician researchers from Roswell Park Comprehensive Cancer Center shows benefits of chemotherapy for many patients with early-stage breast cancer with rare variant histology, or tumor anatomy. These findings were presented by first author Arya Mariam Roy during the American Association for Cancer Research annual meeting.
The DESTINY-Breast09 phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current first-line standard of care.
